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A Commentary on
Outer Retinal Dysfunction on Multifocal Electroretinography May Help Differentiating
Multiple Sclerosis From Neuromyelitis Optica Spectrum Disorder
by Filgueiras, T. G., Oyamada, M. K., Preti, R. C., Apóstolos-Pereira, S. L., Callegaro, D., and
Monteiro, M. L. R. (2019). Front. Neurol. 10:928. doi: 10.3389/fneur.2019.00928
We read with interest the recent manuscript by Filgueiras et al. (1), which presented data
collected using multifocal electroretinography (MF-ERG) in patients with multiple sclerosis (MS),
neuromyelitis optica spectrum disorder (NMOSD), and control subjects. Given that MF-ERG peak
times were slightly shorter (i.e., supernormal) in MS patients relative to both NMOSD patients and
controls, the authors interpreted their findings as evidence of excitatory outer retinal dysfunction
in MS (1). Whilst this is a potentially exciting conclusion, a degree of caution appropriate to the
novelty of the findings is warranted when attempting to interpret these data. In this commentary,
we highlight a number of factors which may influence the conclusions drawn from the work of
Filgueiras (1).
Evidence to date suggests that full-field ERG peak times in patients withMS are typically delayed
(subnormal), with this finding being particularly robust for responses driven, in whole or in part,
by the cone system (2–8). While delays to the ERG a-wave have been recorded (2, 4, 5, 8), it appears
that delays to the b-wave are more common (2–8). The ERG b-wave is generated primarily in the
bipolar cells (9), as is theMF-ERG (10), although both are dependent on functional photoreceptors.
Studies employing the MF-ERG in patients with MS are notably fewer in number than those
employing full-field ERG, with one study documenting normal MF-ERG findings in an early MS
cohort (2) and our group recording responses which were of normal to delayed peak time and
normal amplitude (8). In summary, ERG findings in MS patients to date are almost unanimous in
showing evidence of subnormal cone-driven bipolar cell function, as evidenced by delayed peak
times; MF-ERG evidence to date is sparse, but nevertheless consistent with normal or subnormal,
rather than supernormal, cone-driven bipolar function.
How, then, can we interpret the findings of Filgueiras et al. (1) suggesting supernormal bipolar
function in MS patients in the light of this pre-existing literature, and are there any factors which
may account for this apparent discrepancy? In attempting to reconcile their findings with previous
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work from our group (8), Filgueiras suggested that our findings
may be less reliable due to the use of manufacturers’ normative
databases from our electrophysiology device for comparison,
rather than control data acquired on-site using the same
conditions as for our patient cohort. However, this suggestion is
incorrect: as we stated in our manuscript (8), all normative data
had been previously acquired on-site using the same devices used
for the MS patients. Additionally, electrophysiological protocols
were identical for MS patients and for acquisition of normative
data. This can therefore be discounted as a possible reason for
the discrepancy between the two studies.
In contrast, however, the parameters analyzed differed
between the two investigations. These differences included the
MF-ERG waveform components and retinal areas analyzed. The
exclusion of R5 from analysis by Filgueiras et al. (1), in order to
facilitate comparison with perimetric data, may be particularly
relevant given that we recorded R5 P1 peak times which were
significantly delayed in MS patients relative to normative data
(8). The analysis of different retinal areas makes it challenging
to compare the results of the two studies directly.
Likely the most important factor distinguishing the recent
work of Filgueiras et al. (1) from other studies is the choice
of analyses employed. Despite analyzing numerous outcome
measures, the authors did not correct their published p-values
for multiple testing. Such corrections are essential when testing
multiple hypotheses because the risk of a type 1 (false positive)
error increases with the number of statistical comparisons;
in other words, the greater the number of hypotheses tested,
the greater the possibility of a “statistically significant” result
occurring by chance, unless p-values are corrected. There are
many methods of making such corrections [e.g., the method
of Benjamini and Hochberg (11)], but the simplest (12) is
Bonferroni correction (13). This corrects p-values by dividing
the required level of statistical significance by the number of
hypotheses to be tested. For example, if five hypotheses are tested,
then only p-values < (0.05/5=) 0.01 would reach significance.
Filgueiras analyzed the amplitude and peak time of both N1
and P1 components of the MF-ERG over three retinal areas (R1-
R2, R3-R4, R1-R4) and employed a significance level of 0.05
(1). Eyes were categorized as MS or NMOSD, in addition to
having a history of optic neuritis, and compared with healthy
control eyes. Therefore, a total of 48 hypotheses (4 MF-ERG
parameters∗3 retinal areas∗4 categories) were tested. Applying
Bonferroni correction with a significance level of 0.05, only p-
values< (0.05/48=) 0.001 would reach statistical significance. As
the relevant p-values were not provided, but merely categorized
as being<0.05 or<0.01 [Table 3, (1)], it remains unclear whether
any of the purportedly “significant” findings actually reached the
specified level of statistical significance; if not, then the pattern
of results would be identical (2) or comparable to (8) previously
published work.
Finally, we wish to reiterate that Bonferroni correction is
only one of many potential ways of addressing the statistical
issues raised by multiple hypothesis testing, and moreover is
known to be low-powered and statistically conservative (12)
[conversely, findings which remain significant after Bonferroni
correction of p-values are highly likely to be robust in nature
(14)]. We have employed this method here simply to illustrate
the need for caution when attempting to contextualize the
results documented by Filgueiras et al. (1) without reanalyzing
the dataset. Inhibitory bipolar cell dysfunction in patients with
MS is now well-documented (as discussed above), however
similarities or differences between findings in the central and
peripheral retinae are yet to be definitively elucidated, as is the
utility and clinical relevance of this dysfunction. With regard
to potential excitatory bipolar dysfunction in MS, as Filgueiras
and colleagues correctly state in their manuscript (1), further
studies are required. For these reasons, the currently available
body of evidence appears insufficient to support the existence of
supernormal retinal bipolar cell function in patients with MS.
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